IN2012DN01864A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01864A
IN2012DN01864A IN1864DEN2012A IN2012DN01864A IN 2012DN01864 A IN2012DN01864 A IN 2012DN01864A IN 1864DEN2012 A IN1864DEN2012 A IN 1864DEN2012A IN 2012DN01864 A IN2012DN01864 A IN 2012DN01864A
Authority
IN
India
Prior art keywords
generating
gas discharge
constituted
supported
compound
Prior art date
Application number
Inventor
Christophe Lebon
Pascal Suplie
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of IN2012DN01864A publication Critical patent/IN2012DN01864A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glanulating (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)

Abstract

The present invention relates to a floating granule comprising a solid core, on which an active ingredient is supported and also comprising a compound which is capable of generating a gas discharge which is constituted by an alkaline agent, characterised in that it does not comprise an acid agent which is capable of generating a gas discharge.
IN1864DEN2012 2009-08-12 2010-08-11 IN2012DN01864A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955641A FR2949061B1 (en) 2009-08-12 2009-08-12 FLOATING MICROGRANULES
PCT/FR2010/051691 WO2011018582A2 (en) 2009-08-12 2010-08-11 Floating microgranules

Publications (1)

Publication Number Publication Date
IN2012DN01864A true IN2012DN01864A (en) 2015-08-21

Family

ID=42115979

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1864DEN2012 IN2012DN01864A (en) 2009-08-12 2010-08-11

Country Status (35)

Country Link
US (1) US8916202B2 (en)
EP (1) EP2464333B1 (en)
JP (1) JP6068142B2 (en)
KR (2) KR20120050477A (en)
CN (1) CN102548541B (en)
AR (1) AR077864A1 (en)
AU (1) AU2010283608B9 (en)
BR (1) BR112012003289B1 (en)
CA (1) CA2771053C (en)
CL (1) CL2012000376A1 (en)
CY (1) CY1118119T1 (en)
DK (1) DK2464333T3 (en)
EA (1) EA023532B1 (en)
ES (1) ES2588430T3 (en)
FR (1) FR2949061B1 (en)
HK (1) HK1172824A1 (en)
HR (1) HRP20161149T1 (en)
HU (1) HUE030027T2 (en)
IL (1) IL218072A (en)
IN (1) IN2012DN01864A (en)
LT (1) LT2464333T (en)
MA (1) MA33523B1 (en)
MX (1) MX2012001878A (en)
NZ (1) NZ598468A (en)
PE (1) PE20120805A1 (en)
PL (1) PL2464333T3 (en)
PT (1) PT2464333T (en)
SG (1) SG180305A1 (en)
SI (1) SI2464333T1 (en)
SM (1) SMT201600347B (en)
TN (1) TN2012000068A1 (en)
TW (1) TWI478731B (en)
UA (1) UA107361C2 (en)
WO (1) WO2011018582A2 (en)
ZA (1) ZA201201711B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2562878T3 (en) 2007-05-25 2016-03-08 Indivior Uk Limited Sustained release formulations of risperidone compounds
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID
FR2949062B1 (en) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
US9790774B2 (en) 2014-01-02 2017-10-17 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10301917B2 (en) 2015-07-24 2019-05-28 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
US10626321B2 (en) 2015-07-24 2020-04-21 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
EP3740189A1 (en) * 2017-12-18 2020-11-25 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
JP2022522270A (en) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド Gamma-hydroxybutyrate composition with improved pharmacokinetics in dietary intake
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (en) * 1986-02-24 1987-08-28 Eisai Co Ltd Gastric resident particle
IT1217783B (en) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab USE OF SALO DELL, BUTYRIC HYDROXIC ACID RANGE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR USE IN THE ALCOHOLIC THERAPY AND RELATED COMPOSITIONS
IT1248588B (en) 1991-06-28 1995-01-19 Gaetano Crepaldi PHARMACEUTICAL COMPOSITIONS FOR THERAPY OF ABSTINENCE, "CRAVING", DEPENDENCE ON AMAZING SUBSTANCES, PSYCHOACTIVE SUBSTANCES, NICOTINE AND FOOD DISORDERS.
IT1266565B1 (en) 1993-07-22 1997-01-09 Ct Lab Farm Srl PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE ON THE BASIS OF ONE OR MORE PHARMACEUTICALLY ACCEPTABLE SALTS OF THE RANGE-HYDROXY-BUTYRIC ACID.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (en) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (en) * 1997-04-18 1999-05-14 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION
SE9702533D0 (en) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (en) 1997-07-23 2003-09-16 フロイント産業株式会社 Method for producing single substance spherical particles
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (en) * 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
ES2193777T3 (en) 1998-12-23 2003-11-01 Orphan Medical Inc MICROBIOLOGICALLY STABLE AND INALTERABLE DISSOLUTIONS OF GAMMA-HYDROXIBUTIRATE SALT FOR THE TREATMENT OF NARCOLEPSY.
FR2797185B1 (en) 1999-08-06 2001-10-26 Galenix Dev FLOATING PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE AND A NON-ACTIVE PHASE
FR2823668B1 (en) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques ORODISPERSIBLE EFFERVESCENT TABLETS
AU2002319774B2 (en) 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (en) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals METHOD FOR MANUFACTURING ORALLY ADMINISTRATIVE PHARMACEUTICAL PRODUCT WITH REMOTE AGENTS AND PRODUCT OBTAINED
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
EP1536774A1 (en) 2002-09-04 2005-06-08 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
EP1551372B8 (en) 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
WO2005092297A2 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
HUE053838T2 (en) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Sustained release formulations of nalbuphine
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
CA2633825A1 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
FR2898056B1 (en) 2006-03-01 2012-01-20 Ethypharm Sa SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE
MX2010001071A (en) * 2007-07-27 2010-03-09 Depomed Inc Pulsatile gastric retentive dosage forms.
JP5714910B2 (en) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID
FR2949062B1 (en) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES

Also Published As

Publication number Publication date
AU2010283608B9 (en) 2015-08-27
EA201200269A1 (en) 2012-11-30
IL218072A0 (en) 2012-04-30
FR2949061A1 (en) 2011-02-18
CN102548541B (en) 2015-03-11
CN102548541A (en) 2012-07-04
SMT201600347B (en) 2016-11-10
TW201127419A (en) 2011-08-16
FR2949061B1 (en) 2013-04-19
EP2464333A2 (en) 2012-06-20
HRP20161149T1 (en) 2016-11-18
DK2464333T3 (en) 2016-10-03
ES2588430T3 (en) 2016-11-02
PL2464333T3 (en) 2016-12-30
NZ598468A (en) 2015-05-29
BR112012003289A2 (en) 2020-08-11
SI2464333T1 (en) 2016-10-28
HK1172824A1 (en) 2013-05-03
KR20120050477A (en) 2012-05-18
SG180305A1 (en) 2012-06-28
JP2013501762A (en) 2013-01-17
MA33523B1 (en) 2012-08-01
CL2012000376A1 (en) 2013-01-04
LT2464333T (en) 2016-09-12
MX2012001878A (en) 2012-06-01
UA107361C2 (en) 2014-12-25
BR112012003289B1 (en) 2021-07-13
AU2010283608B2 (en) 2015-07-30
KR20170119743A (en) 2017-10-27
ZA201201711B (en) 2012-11-28
WO2011018582A3 (en) 2011-05-19
PE20120805A1 (en) 2012-07-25
US20120207843A1 (en) 2012-08-16
AR077864A1 (en) 2011-09-28
CA2771053C (en) 2017-05-02
PT2464333T (en) 2016-10-03
CA2771053A1 (en) 2011-02-17
TWI478731B (en) 2015-04-01
CY1118119T1 (en) 2017-06-28
JP6068142B2 (en) 2017-01-25
HUE030027T2 (en) 2017-04-28
AU2010283608A1 (en) 2012-03-29
IL218072A (en) 2016-08-31
TN2012000068A1 (en) 2013-09-19
WO2011018582A2 (en) 2011-02-17
EA023532B1 (en) 2016-06-30
US8916202B2 (en) 2014-12-23
EP2464333B1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
IN2012DN01864A (en)
MX2013008299A (en) Effervescent gamma-hydroxybutyric acid granules.
IN2012DN01859A (en)
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
MY166613A (en) Glycerol levulinate ketals and their use
MX356282B (en) Compositions and methods comprising protease variants.
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
MX2012015187A (en) Method for delivering an active agent.
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
MX2013009175A (en) Compositions comprising peroxy î±-ketocarboxylic acid and methods for producing and using the same.
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
MY159251A (en) Processes for the manufacture of a pharmaceutically active agent
TN2012000507A1 (en) Enteric tablet
WO2011144983A3 (en) An improved process for the preparation of lacosamide
UA100394C2 (en) Lipoic acid pellet composition
MX338405B (en) 2-iminobiotin formulations and uses thereof.
MX2012009537A (en) Solid forms comprising a cyclopropyl amide derivative.
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
WO2010068920A3 (en) Diaminoquinazoline inhibitors of dihydrofolate reductase
TW200940687A (en) Antioxidant agent
WO2011031764A3 (en) Compounds and related methods of use
EA200801449A1 (en) GAP GRANULES
EA201100764A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE STABILIZING AGENT
MY160482A (en) Smoke grenade